Last year, the FDA gave accelerated approval of the antibody aducanumab (marketed as Aduhelm by Biogen) for the treatment of Alzheimer's disease. The approval was based solely on a presumed reduction in the amount of the protein "amyloid" in the brain as assessed by amyloid-PET scans and without evidence of significant clinical effect.| medicalxpress.com
Medical and health news service that features the most comprehensive coverage in the fields of neuroscience, cardiology, cancer, HIV/AIDS, psychology, psychiatry, dentistry, genetics, diseases and conditions, medications and more.| medicalxpress.com
Shading brings 3D forms to life, beautifully carving out the shape of objects around us. Despite the importance of shading for perception, scientists have long been puzzled about how the brain actually uses it. Researchers from Justus-Liebig-University Giessen and Yale University recently came out with a surprising answer.| medicalxpress.com
For decades, the story of Alzheimer's research has been dominated by a battle between A-beta and tau amyloids, both of which can kill neurons and impact the brain's ability to function. A new study suggests, however, that these sticky brain plaques may not be operating alone.| medicalxpress.com
A new pathway that is used by cancer cells to infiltrate the brain has been discovered by a team of Canadian and American research groups led by the Singh Lab at McMaster University. The research also reveals a new therapy that shows promise in blocking and killing these tumors.| medicalxpress.com